You just read:

Sosei Heptares Starts New Clinical Development Program - First Subject Dosed in Phase I Study of HTL0014242, a Selective mGlu5 Negative Allosteric Modulator in Development to Treat Psychiatric and Neurological Disorders

News provided by

Sosei Heptares

13 Dec, 2018, 07:00 GMT